No Data
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
Two abstracts accepted for oral presentation at the 13th London International Cough SymposiumNEW HAVEN, Conn., July 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage bi
Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation
Trevi Therapeutics Initiated at Buy by Rodman & Renshaw
Trevi Therapeutics Initiated at Buy by Rodman & Renshaw
Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $7.
Rodman & Renshaw Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $7
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Trevi Therapeutics(TRVI.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersVenus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:
Massinooo : Is this ticker good to trade?
TrytosaveabitOP Massinooo: It will be eventually! Im still looking for bottom?
Massinooo : I have it for 1.16 you think I should hold?
TrytosaveabitOP Massinooo: If you don’t mind averaging down some if need be? Im sorry! I just can’t say whether to buy or sell? I only say what I’m doing! I would hate to be responsible for someone losing! Grrr! Sorry but I’m rooting for you!
Massinooo : Totally understand bro. I’ll keep an eye on it after market opens and will decide. Thank you bro
View more comments...